Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Wuhan Ruidifu Biotechnology is a specialized life sciences company headquartered in Wuhan, China, focusing on the research and production of core raw materials for the in vitro diagnostics (IVD) industry. The company provides an extensive catalog of high-purity recombinant antigens and monoclonal antibodies tailored for use in various immunoassay platforms, including chemiluminescence, ELISA, and rapid diagnostic tests. Their product portfolio covers critical diagnostic areas such as infectious diseases, cardiac markers, inflammation, and tumor markers. Ruidifu utilizes advanced protein expression platforms across bacterial, yeast, and mammalian cell systems to ensure high bioactivity and consistency in their reagents. In addition to off-the-shelf products, the company offers customized antibody development and protein expression services to meet specific client requirements in the global diagnostic industry.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Wuhan Ruidifu Biotechnology.